Accuray (ARAY) vs InspireMD (NSPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
InspireMD (NSPR) has outperformed Accuray (ARAY) over the past year, losing 80.3% versus a loss of 83.9%. Over five years, NSPR leads with a -88.7% price change compared with -93.6% for ARAY. Accuray is the larger company by market cap ($28.8 million vs $22.3 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARAY | NSPR |
|---|---|---|
| Share price | $0.2414 | $0.48 |
| Market cap | $28.83M | $22.31M |
| 1-day change | -4.74% | -6.61% |
| YTD return | -69.10% | -73.03% |
| 1-year return | -83.86% | -80.33% |
| 5-year return | -93.55% | -88.68% |
| EPS (TTM) | $-0.40 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.10 | $2.54 |
| 52-week low | $0.22 | $0.467 |
| Distance from 52-week high | -88.50% | -81.10% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +593.75% |
| Average volume | 7.19M | 77.47K |
| Shares outstanding | 119.44M | 46.49M |
| Employees | 809 | 127 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Accuray
ARAY stock →Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Healthcare · Medical Devices · 809 employees
About InspireMD
NSPR stock →InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions.
Healthcare · Medical Devices · 127 employees
ARAY vs NSPR FAQ
Which is bigger, Accuray or InspireMD?
Accuray (ARAY) is larger, with a market capitalization of $28.83M compared with $22.31M for InspireMD (NSPR).
Which stock has performed better over the past year, ARAY or NSPR?
NSPR returned -80.33% over the past 12 months, compared with -83.86% for ARAY (price return, excluding dividends). Past performance does not predict future results.
Are Accuray and InspireMD in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.